Mutations of the gene for PTEN-induced kinase 1 (PINK1) are a cause of familial Parkinson's disease (PD). PINK1 protein has been localised to mitochondria and PINK1 gene knockout models exhibit abnormal mitochondrial function. The purpose of this study was to determine whether cells derived from PD patients with a range of PINK1 mutations demonstrate similar defects of mitochondrial function, whether the nature and severity of the abnormalities vary between mutations and correlate with clinical features.
We investigated mitochondrial bioenergetics in live fibroblasts from PINK1 mutation patients using single cell techniques. We found that fibroblasts from PINK1 mutation patients had significant defects of bioenergetics including reduced mitochondrial membrane potential, altered redox state, a respiratory deficiency that was determined by substrate availability, and enhanced sensitivity to calcium stimulation and associated mitochondrial permeability pore opening. There was an increase in the basal rate of free radical production in the mutant cells. The pattern and severity of abnormality varied between different mutations, and the less severe defects in these cells were associated with later age of onset of PD.
Citation: Abramov AY, Gegg M, Grunewald A, Wood NW, Klein C, Schapira AHV (2011) Bioenergetic Consequences of PINK1 Mutations in Parkinson Disease. PLoS ONE 6(10): e25622. https://doi.org/10.1371/journal.pone.0025622
Editor: Mark P. Mattson, National Institute on Aging Intramural Research Program, United States of America
Received: July 20, 2011; Accepted: September 7, 2011; Published: October 17, 2011
Copyright: © 2011 Abramov et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported in part by the Wellcome Trust/MRC Joint Call in Neurodegeneration award (WT089698) to the UK Parkinson's Disease Consortium (UKPDC), and by Kattan Trust. Dr. Abramov is a Parkinson's UK Senior Research Fellow. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding was received for this study.
Competing interests: The authors have declared that no competing interests exist.
Mutations in the gene for PTEN-induced kinase 1 (PINK1) are a cause of autosomal recessive familial Parkinson's disease (PD) . The clinical phenotype of PINK1 mutant PD patients is often indistinguishable from idiopathic, sporadic PD , . Thus the mechanisms by which mutations in this gene can induce dopaminergic cell death are a major focus of interest for those seeking to define the molecular pathogenesis of PD.
The function of the PINK1 protein is not yet defined, although it is known to be targeted to mitochondria , a significant component of PD pathogenesis ,  and is thought to be involved in protection against free radical generation . PINK1 gene mutations or PINK1 silencing result in reduced mtDNA levels, defective ATP production, impaired mitochondrial calcium handling, and increased free radical generation, which in turn result in a fall in mitochondrial membrane potential and an increased susceptibility to apoptosis in neuronal cells, animal models and patient-derived fibroblasts –. Recent studies have also demonstrated that PINK1 can initiate the translocation of parkin to mitochondria and the induction of mitophagy , . Overexpression of parkin protein can rescue the effects of a PINK1 mutation in Drosophila and mammalian cells again suggesting that these two proteins participate in related pathways –.
Many of the studies performed to date to define the role of PINK1 have involved artificial cell models with overexpression of wild-type or mutant PINK1, or knock out in cell or animal models, and few have used endogenous expression of mutant protein in host cells. We have previously published on the biochemical effects of mutant PINK1 expression in PD patient fibroblasts . We have now investigated at the level of the single cell, the bio-energetic effects of endogenously expressed PINK1 mutations in PD cells and demonstrate that the consequences depend upon the specific underlying mutation.
Results and Discussion
Four human fibroblasts with PINK1 mutations - L2123, L2124, L2126 and L1703 had a significant reduction of mitochondrial membrane potential (Δψm) by 14–27%, with the maximal decrease in L2126 carrying the 1366C>T mutation by 27.5±2.1% of control cells (p<0.05; n = 4 experiments; Figure 1A). However, one mutant line, L2122 carrying the same 1366C>T mutation, showed a significantly increased Δψm of 119.9±5.3% (n = 68 cells; n<0.001) relative to the control cell lines C3 and L2132 (Figure 1A).
A-L2122 fibroblasts exhibited a 20% increase (p<0.001) in TMRM fluorescence (i,e, an increased Δψm) compared to controls. Fibroblasts with PINK1 mutations (L2123, L2124, L2126 amd L1703) showed a significant decrease in Δψm compared to control cells. B–G In control, L2122 and L2126 fibroblasts (B–C, F), oligomycin did not affect Δψm; rotenone induced a partial depolarisation; FCCP induced complete depolarisation. In L2123, L2124 and L1703 fibroblasts (D–E, G), oligomycin caused a mitochondrial depolarisation.
To investigate how mutations in PINK1 can induce different effects on the value of Δψm, we explored the roles of different mitochondrial mechanisms important in the maintenance of membrane potential. In cells with normal oxidative phosphorylation, Δψm is maintained by the proton pumping activity of the respiratory chain. However if oxidative phosphorylation is impaired, the F1FO-ATP synthase (complex V) can reverse, hydrolyse ATP and pump protons across the inner membrane to maintain Δψm . Substrate deprivation, such as has been described in PINK1 deficient models, can lead to a similar effect i.e. reversal of complex V . Control cells, C3 (n = 41) and L2132 (n = 16), showed either no response (or a small hyperpolarisation) in response to complex V inhibition by oligomycin (0.2 µg/ml), while subsequent inhibition of complex I by rotenone (5 µM) caused a rapid loss of potential (Figure 1B). This confirms that in human fibroblast cells, Δψm is mainly maintained by respiratory chain function, and that in our system there is no limit to substrate availability.
A similar pattern of oligomycin resistance was seen in the L2122 (n = 31) and L2126 (n = 51) 1366C>T cell lines, which had the highest and lowest resting Δψmrespectively (Figure 1 C and F). In contrast, but in agreement with PINK1 deficient cell models , , oligomycin caused marked mitochondrial depolarisation in L2123 (by 37.6±3.1%, n = 33; figure 1D), L2124 (by 42.1±3.3%; n = 38; figure 1E) and L1703 (by 38.7±2.1%, n = 27; figure 1G). TMRM fluorescence was then significantly reduced in all cell lines by the subsequent addition of rotenone (note almost complete depolarisation in control and L2124 cells). A relatively large further decrease in signal in response to FCCP in L2122 then suggested that complex II activity must also be relatively active as a donor of electrons in these cells.
Provision of additional substrate for complex I (pyruvate/malate) or complex II (methyl succinate) to PINK1 deficient neurons caused an increase in Δψm and restoration of normal maintenance of Δψm . To investigate if a mutation in PINK1 would induce the same effect on mitochondrial substrate delivery, we explored the effect of mitochondrial substrates on the maintenance of Δψm in those cell lines that showed depolarisation in response to oligomycin – L2123, L2124 and L1703. Provision of additional substrates for complex I and II by application of 5 mM pyruvate or/and 5 mM methyl succinate to the media increased Δψm and completely prevented oligomycin-induced mitochondrial depolarisation in 2123 (n = 24), L2124 (n = 28) and L1703 (n = 38) cells (figure 2 A–C).
Application of pyruvate (5 mM) or/and methyl succinate (5 mM) to fibroblasts increased Δψm; Substrate provision prevented the oligomycin induced mitochondrial depolarisation in L2123, L2124 and L1703 fibroblasts.
Mitochondrial redox state
Given our demonstration above that cells with PINK1 mutations are dependent on the availability of respiratory chain substrates, we measured the autofluorescence of NADH and FAD+ as a function of respiratory chain activity and substrate turnover.
In these experiments, the resting level of NADH autofluorescence in the cells was expressed as a ‘redox index’, a function of the maximally oxidized and maximally reduced signals. These were estimated from the response to 1 µM FCCP (which stimulates maximal respiration, completely oxidizing the mitochondrial NADH pool) which was taken as 0%, and the response to 1 mM NaCN (which inhibits respiration, preventing NADH oxidation, and so promoting maximal NADH reduction and maximal autofluorescence) which was taken as 100% (Figure 3A). The total mitochondrial NADH pool was estimated as a difference in arbitrary (arb) units between minimum fluorescence (after FCCP application) and maximum autofluorescence (after NaCN) (figure 3A). The basal redox level in L2122 (31.5±2.8%; n = 44; p<0.05), L2123 (27.8±1.8%; n = 37; p<0.001), L2124 (28.9±2.6%; n = 29; p<0.001) and L1703 fibroblasts (23.5±1.9%; n = 33; p<0.001) was significantly more oxidised compared to control C3 (62.1±3.9%, n = 41) and L2132 (54.6±5.2%; n = 28; Figure 3A–C). Interestingly, the cells with lowest Δψm - L2126 showed the highest redox index (78.9±6.4%, n = 47; Figure 3C). Provision of additional substrate - 5 mM glutamate, induced a significant increase of NADH in L2122, L2123, L2124 and L1703 cells (Figure 3B, C). The total mitochondrial pool of NADH was significantly lower in cells with PINK1 mutations, from 75.6±4.7% of control, p<0.05 in L2122 to 39.5±2.8% of control, p<0.001 in L1703 (Figure 3D).
A–B Graphs demonstrate averaged trace of NADH autofluorescence in control L2132 fibroblasts (A) and L1703 PINK1 mutation (B). Estimation of the %age change in mitochondrial redox level in control cells – L2132 (A) and cells with mutations in PINK1 (B–C). C-Redox state was estimated as: 0 is response to FCCP (maximal rate of respiration and lowest level of mitochondrial NADH) and 100% is response to cyanide (inhibition of respiration with no consumption of NADH in mitochondria; Fibroblasts with PINK1 mutations have lower NADH redox state compared to control fibroblasts (except L2126) that can be normalized by application of 5 mM glutamate (C). D – Total pool of mitochondrial NADH was also significantly lower in fibroblasts with PINK1 mutations.
The redox state (FAD) and mitochondrial level of flavoproteins was estimated in a similar way to NADH (only maximal oxidation with FCCP was taken as 100%, and maximal reduction with NaCN as 0%, Figure 4A). The FAD++ based redox state in L2122 (85.1±4.1%; n = 44; p<0.05), L2123 (87.6±6.8%, n = 37; p<0.05), L2124 (75.8±5.1%, n = 29) and L1703 (89.9±7.8%, n = 33; p<0.001) were significantly more oxidised compare to control C3 (65.4±5.3%, n = 41) and L2132 cells (63.5±5.1%, n = 28; Figure 4 B–C). Addition of substrate for complex II (5 mM me-succinate) normalized the redox level in L2122 and L2124 fibroblasts (Figure 4B–C). Provision of L2123, L2126 and L1703 fibroblasts with methyl succinate also reduced their redox level to control values (Figure 4 B–C). The level of the mitochondrial pool of flavoproteins involved in respiration was 1.55-fold higher in L2122 fibroblasts compare to control (p<0.001; figure 4D) and lower in L2126 (56.4±3.2% of control; p<0.001; Figure 4D). Thus, although L2122 fibroblasts have the same mild substrate deprivation as other PINK1 mutated cells, higher activity of the complex II allows them to maintain high membrane potential.
Quantification of the %age change in FAD++ fluorescence: 100 is response to FCCP and 0% is response to cyanide, averaged traces for control L2132 and fibroblasts with PINK1 mutation L2122 presented in A–B. C-Fibroblasts with PINK1 mutations have increased FAD++ fluorescence than controls. This can be reversed by application of 5 mM Me-succinate to PINK1 mutated cells. D- Values of mitochondrial FAD autofluorescence.
All the patient cell lines with PINK1 mutations showed an increased basal rate of reactive oxygen species generation in mitochondria (figure 5A). The highest rates were observed in L2123 (165.9±6.7 of control rate; n = 37; p<0.05), L2124 (164.8±5.6%; n = 67; p<0.05) and L1703 (169.7±7.8%, n = 56; p<0.001). The application of 5 µM rotenone greatly stimulated ROS production in control cells (1.78-fold increase) but not substantially in PINK1 mutated cells (L2123, L2124, L1703), although the increases in L2122 and L2126 were statistically significant (figure 5A). This suggests that mitochondrial ROS production in the cells with mutations in PINK1 is already activated at basal levels due to the limited availability of complex I-linked substrates.
Fibroblasts with PINK1 mutations displayed a higher basal rate of increase in Mitosox fluorescence, demonstrating a higher basal production of ROS compared to controls. Inhibition of complex I with 5 µM rotenone induced a significant increase in ROS production in control fibroblasts but only a small increase in ROS production in fibroblasts with PINK1 mutation. Histogram demonstrates %age values of rate of Mitosox fluorescence compared to 100% for control (C3) fibroblasts.
PINK1 knockout has been shown to result in inhibition of the mitochondrial Na+/Ca2+-exchanger and mitochondrial calcium overload . Even a physiological calcium stimulus induced further overload of mitochondria with calcium and induced permeability transition pore (PTP) opening and a fall in Δψm. Induction of the calcium signal in fibroblasts by 100 µM ATP (which stimulates purinoreceptors and the release of calcium from the endoplasmic reticulum) did not initiate changes in mitochondrial membrane potential of control (C3, L2132) or mutant (L2122, L2123, L2124, L2126 and L1703) cells (n = 3 experiments; data not shown). This suggests that physiological levels of calcium stimulation may not be sufficient to initiate pathological PTP opening in fibroblasts.
We employed the technique of UV flash photolysis of cells incubated with caged calcium (Ca-NP-EGTA) in order to generate a standard calcium signal free from variations in calcium influx/release. UV induced flash photolysis produced a rapid [Ca 2+]c increase in control fibroblasts C3 (n = 18) and L2132 (n = 32) with no associated change in Δψm (figure 6A–B). L2122 fibroblasts showed no mitochondrial depolarisation in response to [Ca 2+]c elevation (figure 6C). However, the same stimulus in fibroblasts with PINK1 mutations L2123 (n = 23; figure 6 D), L2124 (n = 19; figure 6E), L2126 (n = 21; figure 6F) and L1703 (n = 18; figure 6G) resulted in profound mitochondrial depolarisation. Thus, the enhanced mitochondrial membrane potential of L2122 and the lower ROS production in L2122 cells compared to other PINK1 mutation lines, increased the threshold for PTP opening and fall in Δψm.
Arrows mark UV-induced flash photolysis of cells loaded with Ca-NP-EGTA, fluo-4 and TMRM. In control C3 (A), L2132 (B) and in fibroblast with L2122 mutation (C) demonstrated an increase in [Ca2+]c in response to flash photolysis, with no change in Δψm. In fibroblasts with PINK1 mutations (L2123 –D; L2124 – E; L2126 – F; and L1703-G), flash photolysis induced an increase in [Ca2+]c with profound depolarisation of the mitochondria.
Mutations in the gene for PINK1 are a cause of autosomal recessive Parkinson's disease. PINK1 is a mitochondrial protein and recent studies have indicated that it plays a significant role in mitochondrial function and calcium homeostasis in particular . These observations were derived from the use of cell culture knockouts including primary neuronal cultures from transgenic mouse models of PINK1 deficiency. Previous studies using PINK1 patient fibroblasts have shown defects of oxidative phosphorylation and the electron transport chain, and oxidative stress –. In this study we have for the first time studied PINK1 mitochondrial pathophysiology with single cell analysis of cultured cells derived from patients with PD and PINK1 mutations, in order to dissect the down-stream consequences on mitochondrial function. These cells represent an important model system as they enable the study of the biochemical effects of PINK1 mutations in intact cells devoid of any manipulation of the PINK1 gene, and in the presence of the host patient genomic background.
The PINK1 mutant patient cells manifested multiple mitochondrial defects that paralleled those identified in the PINK1 knockout models described above. PINK1 knockdown by siRNA in human neuroblastoma cells was associated with reduction in glucose uptake at the plasma membrane  and with a reduction in mitochondrial DNA levels, decreased ATP synthesis and respiratory chain activity due to substrate restriction (low glucose), an increase in oxidative stress and abnormal calcium handling , . Growth of PINK1 mutant cells in galactose caused mitochondrial fragmentation .
We have found in single fibroblasts that pathological mutations in PINK1 (L1703, L 2123, L2126) cause a significant reduction in mitochondrial membrane potential and altered redox state (NADH level). As in the PINK1 knockouts , , the PINK1 mutant fibroblast mitochondria switch from the production of ATP, to the consumption of ATP by the F1F0-ATPase in order to maintain their Δψm. Furthermore, as in PINK1 knockouts, this phenomenon in L1703, L 2123, L2124 and L2126 mutants could be reversed by the provision of additional respiratory chain substrates: the increase in respiration in the presence of additional pyruvate resulted in a concomitant switch in the mechanism of Δψm maintenance from hydrolysis of ATP to production of ATP. The limitation in mitochondrial substrates seems to be a key point in PINK1 pathology. The increased activity in complex II (measured as FAD+ autofluorescence) in L2122 fibroblasts compensates for low NADH levels and leads to higher mitochondrial membrane potential, and protection against calcium induced PTP opening.
However, there were differences between the fibroblasts and neuronal models; we found significantly less cytosolic reactive oxygen species (ROS) production in PINK1 mutant fibroblasts compared to PINK1 knockout neurons that may be explained by a difference in NADPH oxidase activity. This would fit with our previous observations of normal glutathione levels and no increase in cytosolic oxidation in PINK1 mutant fibroblast cultures . PINK1 mutant cells with low Δψm (L1703, L 2123, L2124 and L2126) were vulnerable to calcium stimulation and produced PTP opening (Figure 6). Furthermore, enhanced physiological calcium stimulation in PINK1 knockout neurons lead to mitochondrial PTP opening while the calcium stimulus in PINK1 mutant fibroblasts did not show mitochondrial depolarization. Fibroblast and neuronal cells are known to differ in their regulation of calcium homeostasis and in the role of mitochondria in calcium buffering . Importantly, using artificial calcium stimulation (flash photolysis) in fibroblasts, we found that this induced opening of the PTP in cells with pathological mutations (figure 6). Our experimental conditions have therefore allowed us to demonstrate a defect in mitochondrial calcium regulation in these mutant cells that cannot be visualized with physiological stimulation.
Interestingly, the patient with the L2122 mutation had elevated Δψm and lower ROS production and so an increased threshold for PTP opening and fall in Δψm compared to other PINK1 mutation lines. This patient also had the latest age of onset for PD (age 61 y) compare to the other PINK1 mutant PD patients. Although L2122 patient cells had the same mild substrate deprivation as other PINK1 mutated cells, the higher activity of complex II allowed the L2122 cells to maintain high membrane potential.
These studies have demonstrated that fibroblasts from PD patients with PINK1 mutations exhibit very similar bio-energetic mitochondrial abnormalities to knockdown cell models. These patient cells also show that there is substrate dependent limitation on ATP synthesis that can be overcome with substrate replacement or normalization of glucose uptake. This may offer an interesting opportunity to explore in terms of disease modifying therapy in these patients, for which there is some precedent in patients with primary mitochondrial encephalomyopathies . These data also indicate that patients with different PINK1 mutations, but affecting the same domain, can show different biochemical phenotypes. It is notable that the patient with the mildest defect of mitochondrial biochemistry (L2122) had the latest onset of disease. Whether this observation indicates a valid correlation with disease severity will require further work in additional patients.
The defects of mitochondrial function in PINK1 mutant patient cells described here have relevance to the part that PINK1 and parkin play in the removal of mitochondria by mitophagy . It has recently been demonstrated in Drosophila and in mammalian cells that parkin ubiquitinates mitofusins 1 and 2, and this function is PINK1 dependent , . This has also recently been demonstrated in fibroblasts from PD patients with PINK1 mutations . Knockdown of PINK1 causes mitochondrial dysfunction and accumulation of defective mitochondria. Overall cellular mitochondrial function can be restored by parkin overexpression and restoration of mitophagy pathways . Thus, the abnormalities of energy metabolism and oxidative stress observed in our PINK1 mutant patient cells will have a deleterious synergy with the parallel impairment of mitophagy, leading to the accumulation of defective mitochondria with the consequent impairment of ATP synthesis and increased free radical production. Such effects are likely to contribute to dopaminergic neuronal cell dysfunction and death.
Five patients in this study were diagnosed with PD and their clinical details have been presented previously . The mutations in PINK1 and the basic clinical characteristics are summarized in Table 1. In these studies, patient 2132 served as a negative control i.e. a family member with no mutation and no disease (at age 35 years). A further control fibroblast line was used from an age-matched control at the same passage number as the PINK1 mutant cells. All analyses were performed and patient samples obtained with the approval of the local ethics committee [University of Lubeck] and the written informed consent of the subjects involved.
Patient and control cells were cultured as previously described .
Loading of cells
For measurements of [Ca2+]c and Δψm, cells were loaded for 30 min at room temperature with fluo-4 AM in combination with 25 nM tetramethylrhodamine methylester (TMRM) and 0.005% pluronic acid in a HEPES-buffered salt solution (HBSS) composed of (mM): 156 NaCl, 3 KCl, 2MgSO4, 1.25 KH2PO4, 2 CaCl2, 10 glucose and 10 HEPES; pH adjusted to 7.35 with NaOH. For flash photolysis experiments, caged Ca2+, 10 µM o-nitrophenyl EGTA, AM (NP-EGTA, AM) was loaded at the same time as the other indicators.
For measurements of Δψm, cells were loaded with 25 nM TMRM for 30 mins at room temperature and the dye was present during the experiment. TMRM is used in the redistribution mode to assess Δψm, and therefore a reduction in TMRM fluorescence represents Δψm depolarisation.
For measurement of mitochondrial ROS production, cells were pre-incubated with MitoSOX (5 µM, Molecular Probes, Eugene, OR) for 10 mins at room temperature.
Imaging of [Ca2+]c and Δψm, ROS and autofluorescence of NADH and FAD++
Confocal images were obtained using a Zeiss 510 uv-vis CLSM equipped with a META detection system and a 40× oil immersion objective. The 488 nm Argon laser line was used to excite fluo-4 fluorescence which was measured using a bandpass filter from 505–550 nm. Illumination intensity was kept to a minimum (at 0.1–0.2% of laser output) to avoid phototoxicity and the pinhole set to give an optical slice of ∼2 µm. TMRM and MitoSOX were excited using the 543 nm laser line and fluorescence measured using a 560 nm longpass filter. NADH autofluorescence was excited at 351 and measured at 410 nm. 2-NDBG was excited at 458 nm, and fluorescence was measured at 520 nm. All data presented were obtained from at least 5 coverslips and 2–3 different cell preparations.
Conceived and designed the experiments: AYA AHVS. Performed the experiments: AYA MG AG. Analyzed the data: AYA CK NWW AHVS. Contributed reagents/materials/analysis tools: AYA MG AG NWW CK AHVS. Wrote the paper: AYA AHVS. Reviewed draft of the manuscript: MG AG CK.
- 1. Valente EM, bou-Sleiman PM, Caputo V, Muqit MM, Harvey K, et al. (2004) Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304: 1158–1160.
- 2. Valente EM, Salvi S, Ialongo T, Marongiu R, Elia AE, et al. (2004) PINK1 mutations are associated with sporadic early-onset parkinsonism. Ann Neurol 56: 336–341.
- 3. Tan EK, Yew K, Chua E, Puvan K, Shen H, et al. (2006) PINK1 mutations in sporadic early-onset Parkinson's disease. Mov Disord 21: 789–793.
- 4. Schapira AH (2008) Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol 7: 97–109.
- 5. Schapira AH, Tolosa E (2010) Molecular and clinical prodrome of Parkinson disease: implications for treatment. Nat Rev Neurol 6: 309–317.
- 6. Gautier CA, Kitada T, Shen J (2008) Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress. Proc Natl Acad Sci U S A 105: 11364–11369.
- 7. Gandhi S, Wood-Kaczmar A, Yao Z, Plun-Favreau H, Deas E, et al. (2009) PINK1-associated Parkinson's disease is caused by neuronal vulnerability to calcium-induced cell death. Mol Cell 33: 627–638.
- 8. Gegg ME, Cooper JM, Schapira AH, Taanman JW (2009) Silencing of PINK1 expression affects mitochondrial DNA and oxidative phosphorylation in dopaminergic cells. PLoS One 4: e4756.
- 9. Hoepken HH, Gispert S, Morales B, Wingerter O, Del TD, et al. (2007) Mitochondrial dysfunction, peroxidation damage and changes in glutathione metabolism in PARK6. Neurobiol Dis 25: 401–411.
- 10. Piccoli C, Sardanelli A, Scrima R, Ripoli M, Quarato G, et al. (2008) Mitochondrial respiratory dysfunction in familiar parkinsonism associated with PINK1 mutation. Neurochem Res 33: 2565–2574.
- 11. Grunewald A, Gegg ME, Taanman JW, King RH, Kock N, et al. (2009) Differential effects of PINK1 nonsense and missense mutations on mitochondrial function and morphology. Exp Neurol 219: 266–273.
- 12. Gispert S, Ricciardi F, Kurz A, Azizov M, Hoepken HH, et al. (2009) Parkinson phenotype in aged PINK1-deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neurodegeneration. PLoS One 4: e5777.
- 13. Narendra DP, Jin SM, Tanaka A, Suen DF, Gautier CA, et al. (2010) PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. PLoS Biol 8: e1000298.
- 14. Vives-Bauza C, Zhou C, Huang Y, Cui M, de Vries RL, et al. (2010) PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. Proc Natl Acad Sci U S A 107: 378–383.
- 15. Clark IE, Dodson MW, Jiang C, Cao JH, Huh JR, et al. (2006) Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 441: 1162–1166.
- 16. Gegg ME, Cooper JM, Chau KY, Rojo M, Schapira AH, et al. (2010) Mitofusin 1 and mitofusin 2 are ubiquitinated in a PINK1/parkin-dependent manner upon induction of mitophagy. Hum Mol Genet 19: 4861–4870.
- 17. Poole AC, Thomas RE, Andrews LA, McBride HM, Whitworth AJ, et al. (2008) The PINK1/Parkin pathway regulates mitochondrial morphology. Proc Natl Acad Sci U S A 105: 1638–1643.
- 18. Yang Y, Ouyang Y, Yang L, Beal MF, McQuibban A, et al. (2008) Pink1 regulates mitochondrial dynamics through interaction with the fission/fusion machinery. Proc Natl Acad Sci U S A 105: 7070–7075.
- 19. Exner N, Treske B, Paquet D, Holmstrom K, Schiesling C, et al. (2007) Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin. J Neurosci 27: 12413–12418.
- 20. Dagda RK, Cherra SJ III, Kulich SM, Tandon A, Park D, et al. (2009) Loss of PINK1 function promotes mitophagy through effects on oxidative stress and mitochondrial fission. J Biol Chem 284: 13843–13855.
- 21. Campanella M, Casswell E, Chong S, Farah Z, Wieckowski MR, et al. (2008) Regulation of mitochondrial structure and function by the F1Fo-ATPase inhibitor protein, IF1. Cell Metab 8: 13–25.
- 22. Morais VA, Verstreken P, Roethig A, Smet J, Snellinx A, et al. (2009) Parkinson's disease mutations in PINK1 result in decreased Complex I activity and deficient synaptic function. EMBO Mol Med 1: 99–111.
- 23. Scheele C, Nielsen AR, Walden TB, Sewell DA, Fischer CP, et al. (2007) Altered regulation of the PINK1 locus: a link between type 2 diabetes and neurodegeneration? FASEB J 21: 3653–3665.
- 24. Mattson MP (2007) Calcium and neurodegeneration. Aging Cell 6: 337–350.
- 25. Leonard JV, Schapira AH (2000) Mitochondrial respiratory chain disorders I: mitochondrial DNA defects. Lancet 355: 299–304.
- 26. Whitworth AJ, Pallanck LJ (2009) The PINK1/Parkin pathway: a mitochondrial quality control system? J Bioenerg Biomembr 41: 499–503.
- 27. Ziviani E, Tao RN, Whitworth AJ (2010) Drosophila parkin requires PINK1 for mitochondrial translocation and ubiquitinates mitofusin. Proc Natl Acad Sci U S A 107: 5018–5023.
- 28. Rakovic A, Grunewald A, Kottwitz J, Bruggemann N, Pramstaller PP, et al. (2011) Mutations in PINK1 and Parkin impair ubiquitination of Mitofusins in human fibroblasts. PLoS One 6: e16746.
- 29. Hedrich K, Hagenah J, Djarmati A, Hiller A, Lohnau T, et al. (2006) Clinical spectrum of homozygous and heterozygous PINK1 mutations in a large German family with Parkinson disease: role of a single hit? Arch Neurol 63: 833–838.